Two U.Va. spin-off companies have been selected to present at the 2012 Mid-Atlantic Biotech Conference, to be held Sept. 27-28 in Bethesda, Md.
Charlottesville-based ADial Pharmaceuticals LLC and Xdynia will join 20 other companies from Maryland, North Carolina, Pennsylvania and Virginia in presenting to an estimated 850 conference attendees, including investors. Both companies will present in the conference’s “Emerging Growth” category, which features companies seeking investment for “promising technologies or products” in development.
ADial will showcase its emerging treatment for alcoholism.
“Alcoholism is a debilitating diseases that afflicts over 200 million people worldwide,” said William Stilley, CEO of ADial. “Our drug, AD04, effectively treats alcoholism by reducing the harm from drinking among those with specific genetics.
“ADial is excited to have the opportunity to shed more light on the disease and treatment of alcoholism at Mid-Atlantic Bio.”
Founded earlier this year, Xdynia will present drugs that could be used to prevent and treat neuropathic pain, such as the chronic pain caused by diabetes, shingles, fibromyalgia, cancer, HIV, trauma and phantom limb.
Read the full story here.